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Depression is one of the most prevalent and debilitating public health concerns. Although no single cause of depression has been
identiﬁed,itappears thatinteractionamonggenetic,epigenetic, biochemical,environmental,andpsychosocialfactorsmayexplain
its etiology. Further, only a fraction of depressed patients show full remission while using current antidepressants. Therefore,
identifying common pathways of the disorder and using that knowledge to develop more eﬀective pharmacological treatments
are two primary targets of research in this ﬁeld. Brain-enriched neurotransmitter CART (cocaine- and amphetamine-regulated
transcript) has multiple functions related to emotions. It is a potential neurotrophic factor and is involved in the regulation of
hypothalamic-pituitary-adrenal axis and stress response as well as in energy homeostasis.CART is also highly expressed in limbic
system, which is considered to have an important role in regulating mood. Notably, adolescents carrying a missense mutation in
the CART gene exhibit increased depression and anxiety. Hence, CART peptide may be a novel promising antidepressant agent. In
this paper, we summarize recent progress in depression and CART. In particular, we emphasize a new antidepressant function for
CART.
1.Introduction
Depression or major depression disorder (MDD) is one of
the most prevalent and debilitating public health concerns.
MDD aﬀects millions ofpeople each year [1, 2], and the bur-
denofthis disease will continuetoincrease, especially during
the extra years oflife gained from improved health outcomes
in cardiovascular disease, cancer, and other domains [3, 4].
Notably evidence showed that MDD aﬀects more women
than men [5].
According to the guidelines developed by the American
Psychiatric Association, MDD can be diagnosed when a
patient demonstrates at least 2 weeks of depressed mood or
lossofinterestaccompaniedbyatleastfouradditionalsymp-
toms, including constant sadness, irritability, hopelessness,
trouble sleeping, low energy or fatigue, feeling worthless or
guilty for no reason, signiﬁcant weight change (gain or
loss), diﬃculty concentrating, and loss of interest in favorite
activities [5, 6]. However, the etiology and pathology of this
serious biologic disease are still largely unknown. It is likely
the result of a complex interaction of genetic, epigenetic,
biochemical, environmental, and psychosocial factors.
Now, there is compelling evidence that monoaminergic
neurotransmission in the brain is disturbed in depressed
patients. However, usually it takes between 1 and 6 weeks for
the current antidepressant medicines to exert their clinical
eﬀects. This latency is thoughtto be a problemin the therapy
of MDD, since many patients have a high risk of committing
suicide. Furthermore, only 50% of patients with MDD show
full remission while receiving currently available antidepres-
sants [4]. Thus, faster and more eﬀective pharmacological
treatments for MDD are greatly needed.
The cocaine- and amphetamine-regulated transcript
(CART) peptides are among the newest putative peptide
neurotransmitters [7–10]. It recently has been hypothesized
to be an interesting neuropeptide that might be relevant to2 Depression Research and Treatment
the treatment of depression [11]. CART peptides show no
signiﬁcant homology to any other peptide, and as discussed
below, they have unique structure, expression and multiple
roles in several physiological processes. CART peptides are
involved in reward and reinforcement, feeding, sensory
processing, stress response, and endocrine control. CART
also regulates monoaminergic neurotransmission and neu-
rotrophic factors such as brain-derived neurotrophic factor
(BDNF). Interestingly, previous research on the activity of
CART established an important connection between this
peptide and mitochondria, the energy producing structures
in most cells [12]. More importantly, animal studies have
shown an antidepressant eﬀect for CART peptides. There-
fore,CARTmaybeanewantidepressantcandidatewithgreat
promise for future clinical utility.
2.RecentProgressof Depression
To date, the etiopathogenesis of MDD is still unknown.
Despite the limited knowledge available to explain the cause
and molecular mechanisms underlying this disease, there
are several hypotheses and related eﬀective treatments for
depressed patients.
The widely used tricyclic compound imipramine and the
antituberculosis drug iproniazid were early treatments that
eﬀectively treated depression. Both drugs cause elevation of
extracellular monoamine levels by either blocking mono-
amine oxidase (MAO) (like iproniazid) or by inhibiting the
neuronal serotonin and/or noradrenaline transporter (like
imipramine and its active metabolite desipramine). These
drugs’ eﬀectiveness led to the hypothesis that depression
(aﬀective disorders) is due to the central nervous system
(CNS) “catecholamine deﬁciency”. Later, the introduction
of selective serotonin reuptake inhibitors (SSRIs such as
ﬂuoxetine)drovethe“monoamine deﬁciency”hypothesis[6,
13]. Interestingly, serotonin is thought to regulate neurode-
velopmental processes through maternal-fetal interactions
thathavelong-termmentalhealthimplications, andrecently,
it has been discovered that there is a placental serotonin
synthetic pathway from a maternal tryptophan precursor in
both mice and humans [14]. Since monoamine (including
serotonin) enhancers improve depressive symptoms, the
monoamine hypothesis continues to be a prominent preoc-
cupation of the ﬁeld, and the pathway of monoaminergic
transmission continues to be the one of the key targets
of new medications. However, many studies, including
genetic association analyses examining polymorphisms in
monoaminergic genes, provide little evidence to implicate
true deﬁcitsin serotonergic, noradrenergic, or dopaminergic
neurotransmission in the pathophysiology of depression [4,
15].
Beyond the serotonin hypothesis, increasing evidence
strongly suggests components of mitochondrial dysfunc-
tion/oxidativestress andinﬂammation inthepathogenesisof
depression and other aﬀective spectrum disorders [16–18].
These three concepts of monoamines, energy metabolism,
and inﬂammatory pathways are interrelated in many com-
plex manners. For example, the major categories of drugs
used to treat depression have also been demonstrated to
exert eﬀectson mitochondria and inﬂammation. Conversely,
commonly used mitochondrial-targeted treatments exert
eﬀects on mitochondria and inﬂammation, and are increas-
ingly being shown to demonstrate eﬃcacy in the aﬀective
spectrum disorders [17]. These observations indicate that
mitochondria protection orstimulating mitochondrial func-
tion is an important therapeutic approach for treatment of
depression and related diseases.
Over the last several years, genome-wide association
studies (GWAS) have become a powerful tool for unraveling
the genetic foundations of complex disorders such as major
depression. A recent GWAS analysis [19] also suggests that
HOMER1 plays a role in the etiology of major depression.
Observations from homer1 knockout mice and human
imaging genetics study indicate the importance of cortical-
limbic circuitry in the development of MDD. It is of
great interest that CART and Homer1 have already been
implicatedinapreviousreport[20].Inthisstudy,microarray
analysis and real-time polymerase chain reaction (PCR)
showed both genes were similarly downregulated in the
frontal cortex of rats exposed to the chronic mild stress
paradigm, an animal model of human depression.
On the other hand, depression is frequent psychiatric
disorder in neurodegenerative diseases such as Alzheimer’s
disease (AD) and multiple sclerosis [21–23], suggesting there
is an important mechanism that neurodegeneration or neu-
ronlossnotonlyunderliesdementiaandmovementdisorder
but also causes depression. Neuropsychiatric symptoms are
c o m m o nev e ni nt h ee a r l ys t a g e so fA D[ 22]. Depression also
decreases the quality of life but may remain unrecognized in
AD patients [22]. Some of AD patients develop psychosis as
the disease progresses. The associations of candidate genes
f o rt h i st y p eo fA Dh a v ea l s ob e e ni n d i c a t e dw i t ht h em o n o -
amine neurotransmitter system and dopamine system [24].
Importantly, loss of cholinergic neurons and/or dysfunc-
tion of the glutamatergic system in CNS cause learning
impairment in AD patients and experimental AD animals.
Further, the impaired cholinergic system is likely implicated
in depressive behaviors in AD patients. Neurogenesis per-
sistently occurs in the forebrain subventricular zone (SVZ)
and hippocampal subgranular zone (SGZ) in rodent and
human brains. Impaired neurogenesis in those regions is
implicated not only inmemory deﬁcitsbutalso in depressive
behaviors. It has been found that olfactory bulbectomized
(OBX) mice reveal memory impairment and depressive
behaviors [25]. A novel cognitive enhancer, ZSET1446, that
is a new azaindolizinone derivative improved learning and
memory in the hippocampus of amyloid-beta infused rats.
Notably, ZSET1446 increased neurogenesis and improved
depressive behavior [25]. These therapeutic data suggest
that neurodegeneration or impaired neurogenesis in the
brain may be an important and common mechanism of
the depression and learning/memory/cognitive impairment
observed in AD animal models and AD patients.
Furthermore, neurotrophins are important regulators of
neurogenesis and neuronal plasticity in the developing and
adult brain. Neurotrophin signalling has also been strongly
linked in mood disorders. Recent studies on neurotrophicDepression Research and Treatment 3
factors, in particular BDNF, have indicated that mental dis-
orders reﬂect failed function of critical neuronal networks,
whereas a gradual network recovery through activity-de-
pendent neuronal plasticity or adaptability induces the
antidepressant eﬀect [26, 27]. These intense investigations
on neurotrophic factors have led to the formulation of the
neurotrophic hypothesis of depression, which will continue
to be a critical event in the pathophysiology and therapy of
major depression.
Recent ﬁndings suggest that early childhood events and
adult stress produce neurodegenerative changes in the brain
that can eventually lead to breakdown of the neuronal net-
works regulating mood [28, 29]. Therefore, genetic and/or
functional defects in the critical neural networks may be
the fundamental event of the major depression. In addition,
environmental stimulations such as stress may eventually
cause the major depression disorder.
3.MolecularFeaturesand FunctionsofCART
The CART or CARTPT (CART prepropeptide) gene was
discovered from rat brain in 1995 by PCR diﬀerential display
in a search for gene transcripts in the striatum acutely up-
regulatedbypsychostimulants[7,10].CARTisauniquegene
without signiﬁcant homologues, and well conserved across
species—from ﬁshes to mammals and humans. Its human
chromosome location is 5q13.2 (GenBank accession num-
ber and locus: NG 015988; homo sapiens CART/CARTPT
mRNA accession number: NM 004291). In the rat brain,
the primary CART transcript is diﬀerentially spliced and the
two mRNAs encode CART prepropeptides of either 116 or
129 amino acids (a.a.) [7]. The leader sequence of CARTPT
consists of 27 a.a. and mature CART peptides, therefore,
c o n t a i ne i t h e r8 9o r1 0 2r e s i d u e s[ 7]. Only the former form
of CART (89 a.a. long) is present in human tissue [30].
CART peptide processing is tissue dependent and two forms
predominate in the rat brain: CART (42–89) and CART
(49–89) [31]. These C-terminal ends of CART, consisting of
48 or 41 amino acid residues (long form and short form,
resp.) and 3 disulphide bonds, are thought to constitute
a biologically active part of the molecule. Many studies
subsequently showed that both of these peptides are active,
and they may have diﬀerent actions.
As shown in the ﬁrst CART paper [7], CART is expressed
in the striatum, as well as its ventral extension, the nucleus
accumbens (NAc), further CART peptide immunoreactivity
are also located in a number of hypothalamic structures
involved in the control of feeding behavior, stress response,
and body homeostasis, such as the lateral hypothalamic
area, the paraventricular and arcuate nuclei [10, 30, 32–34].
Consistent with these anatomical observations, a number
of groups have shown that intracerebroventricular (ICV)
administration of CART peptides inhibits food intake in rats
and mice [10, 34]. CART knockout mice displayed increased
body weight at the age of 40 weeks or when oﬀered a high
caloric diet, further indicating that CART is required for
maintaining normal body weight and energy homeostasis
[35, 36].
CART contains three disulﬁde bridges in its C-terminal
part. This unique structure is not known to exist in
other peptides/proteins [37], and this impact structure may
increase CART’s permeability across most cellular mem-
branes. In fact, a previous report showed that CART readily
passes through the blood-brain-barrier after intravenous
injection, and the entry of CART into brain is rapid and
not inhibited by excess CART or leptin [38]. This feature
may facilitate CART use in animals (including primates) and
humans in the future.
Recently, using primary neuronal cell culture, we found
that CART has an important transcription activity when
fusing the CART C-terminal to the yeast Gal4 DNA-binding
domain [39]. This function may explain itsregulation role in
the expression of several genes, including BDNF. However,
the detail molecular mechanisms as well as the relationship
between this transcription activity and behaviors need to be
further elucidated.
4.Depression and CARTinGenderDifference
Although MDD aﬀects men and women of all ages, races,
and economiclevels,women are at a signiﬁcantly greater risk
than men to develop major depression. Studies show that
episodesof depressionoccurtwiceas frequentlyin womenas
in men [5, 40]. The mechanisms underlining this phenotype
are not fully understood. Sex diﬀerences in the structure
or function in stress-responsive systems may play a role
in female vulnerability to the disease. It has been shown
that the major brain norepinephrine- (NE-) containing
nucleus, locus coeruleus (LC), is more sensitive to stres-
sors and to the stress-related neuropeptide, corticotropin-
releasing factor (CRF) in female compared to male rats [41,
42]. Further, the greater dendritic extension and complexity
seen in females predicts a higher probability of commu-
nication with diverse aﬀerents that terminate in the peri-
LC. This may be a structural basis for heightened arousal
in females, an eﬀect which may, in part, account for the
sex bias in incidence of stress-related psychiatric disorders
[43].
Thenonpreganglionic Edinger-Westphalnucleus(npEW)
in midbrain has also been implicated in regulation of the
stress response. CART and BDNF are sex-speciﬁcally in-
volved in the stress response too, and are present in the
human and rat npEW [44]. Immunocytochemistry and in
situ hybridization have shown that BDNF, CART and the
estrogen receptor beta (ERbeta) are colocalized in the npEW.
Quantitative immunocytochemistry revealed a 16% lower
number of BDNF-immunoreactive neurons, and 19% lower
CART-immunoreactivity in females comparedto males [44].
Furthermore, chronic stress increased the amount of CART
andnesfatin-like immunoreactivityinbothmales andfemale
rats [45], indicating a ﬁrmed adaptive change in these long
term-stressed animals. In a mouse study, acute (restraint)
stress stimulates the general secretory activity of these
npEW neurons as determined by increased presence of Fos,
and the production of CART, urocortin-1 (Ucn1) mRNAs
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Therefore, CART, Ucn1 and nesfatin-1/NUCB2 are speciﬁ-
cally involved in the response of npEW neurons to stress.
Considering the fact that CART, Ucn1, and BDNF are
coexpressed in the npEW with ERbeta, and their protein
expression diﬀers between males and females, the authors
proposed that the functioning of the npEW may contribute
to the sex diﬀerences that exist in stress sensitivity [44,
46].
Further, stress exposure and diet have diﬀerential eﬀects
on CART and BDNF that are sex dependent [47]. Chronic
mild stress, a widely recognized animal model of depression,
showed that gene for neuropeptide Y was upregulated in
female rats purely in response to stressors, whereas genes
for CART, BDNF, and arginine vasopressin (AVP) in males,
and leptin in females, exhibited a signiﬁcant response to
the interaction between stressors and diet. Every aﬀected
gene showed a diﬀerent pattern of expression in males and
females. Therefore, this study further supports a neurobio-
logical basis for diﬀerences in the aﬀective state response to
stress in males and females [47].
The CART levels in mesolimbic brain areas have also
been analyzed [48]. The speciﬁc expression of the CART
transcript in the ventral striatum, the amygdaloid complex,
and the amygdala hippocampal area, strongly suggests an
involvement of CART in emotion, motivation, and reward
[48, 49]. Furthermore, it has been shown that CART expres-
sion is regulated by stress in a regionally and time-speciﬁc
manner and that CARTis regulated by corticosteroid actions
in the hippocampus [49]. Also interestingly, it has been
found that a gender diﬀerence in the basal CART mRNA
expressionthatwasrestrictedtothenucleusaccumbensshell.
Male rats expressed higher levels of CART mRNA in this
region than did female rats [48].
Such diﬀerent features between female and male in brain
may be due to gonadal hormones and the interaction be-
tween hormone, stress, and brain [40, 50–52]. Gonadotro-
pin-releasing hormone (GnRH) is the pivotal hypothalamic
hormone regulating reproduction and related behaviors
[53]. As mentioned above, CART has a transcription activity
in neuron cells, it has been shown that CART (42–89)
is also involved in regulation of GnRH in hypothalamus
[54]. The release of GnRH is intricately related to sex
steroid hormones, especially neuroprotective estrogen [55–
57]. Recent study showed that estrogen can promote stress
sensitivity in a prefrontal cortex-amygdala pathway [58]. On
the other hand, estrogen can increase CART production
in cortical neurons [59]. Further CART increases expres-
sion of a key neurotrophic factor BDNF, which mediates
neuronal growth, neuroprotection, and synaptic modulation
in hippocampal neurons [60]. BDNF is also associated
to the pathology of depression and is thought to be a
key target in the treatment of major depression [61, 62].
Taken together, CART and its association factors such as
BDNF, estrogen/estrogen receptor, may be involved in the
gender diﬀerent mechanism in stress and depression. To
date, however, CART serum levels in normal human and
patientswithmentaldiseases(includingMDD),inparticular
the relationship between CART and gender have not been
reported.
5.AntidepressantActionofCART
5.1. Antidepressant Action of CART in Animal Studies. CART
peptide and mRNA are present in brain regions that are
associated with depression, including the hippocampus, the
locus coeruleus, parts of the midbrain raphe nuclei, the
amygdale, and the hypothalamus [7, 48, 49, 63]. It was
recently demonstrated that CART mRNA is downregulated
in the frontal cortex of rats that have been subjected to a
chronic mild-stress paradigm, which is an animal model of
depression [20], indicating that chronic mild-stress inhibits
normal CART expression in the frontal cortex. However,
another recent report provided evidence for the CART
peptide being signiﬁcantly increased in the periaqueductal
grey in a genetic rat model of depression [64]. This increased
expression of CART may represent an adaptation to the
transgenic depression model, it has been considered that the
adaptation changes may be the key to treatment of some
diseases, especially stress-related disorders [65].
To investigate the eﬀect of CART peptide on depression,
two depression-like behavioral rat models (i.e., socially
isolated and olfactory bulbectomized, OBX) were used.
Administration of CART (54–102) into the lateral ventricle
(50–100ng) or central nucleus of amygdala (CeA) (10–
20ng) caused signiﬁcant decrease in immobility time in the
forcedswim test(FST)withoutinﬂuencinglocomotion.This
suggests that the CART peptide may have an antidepressant-
like eﬀect [66]. Social isolation as well as OBX models were
undertakento produce depression-like conditions. Although
isolation reared (6 weeks) rats showed signiﬁcant increase
in immobility time in FST, OBX animals exhibited hyper-
activity (increase in the ambulation, rearing, grooming, and
defecation scores) on day 14 in the open-ﬁeld test. The
isolation- or OBX-induced depression-like phenotypes were
reversed following acute or subchronic treatment of CART,
respectively, given via ICV and intra-CeA routes. Drastic
reduction in CART-immunoreactivity was observed in most
cells in PVN, arcuate and Edinger-Westphal nuclei of the
socially isolated and OBXanimals. Althoughthe ﬁbers in the
paraventricular nucleus (PVN) showed variable response,
those in the arcuate nucleus (ARC) and prefrontal cortex
did not change. The CART-immunoreactive ﬁbers in the
locus coeruleus also showed highly signiﬁcant reduction.
However, dramatic increase in CART-immunoreactive ﬁbers
was noticed in the CeA in both experimental models.
These data demonstrated the antidepressant role of CART
when using lower doses (even 10ng), and underscores the
important fact that theendogenousCARTsystemmight play
a major role in mediating symptoms of depression. Since
there are several biologically active forms of CART, and they
mayhavesimilar ordiﬀerenteﬀectsonthedepressionmodel,
other main forms of CART should also be tested in the
future. This is still interested in the ﬁeld.
Similarly, as discussed above, CART expression levels
were signiﬁcantly increased in the rat NAc after electro-
convulsive therapy, which also suggests a beneﬁcial role for
CART as an antidepressant treatment [67]. It is important
to mention that in these antidepressant studies and our
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was much lower than that of food intake studies [34]. This
indicatesthatCARTfunctions primarily as anantidepressant
at physiological concentrations, which is further supported
by other studies both in vitro and in vivo [59, 60]. Paradoxi-
cally, an anxiety-like eﬀect has also been observed in animal
studies as discussed below (Section 7). Multiple factors such
as dosage, structure and size of the CART peptide used may
play a role in causing anxiety. From this point, anxiety-like
behavior may be a side eﬀect of CART peptide usage, but
this needs more studies for clariﬁcation. Then, the CART
molecule(structure,size,anddose)canbeselectedorfurther
modiﬁed to improve its eﬃcacy as an antidepressant, with
minimal side eﬀects.
5.2. Antidepressant Action of CART in Human. There is
no report regarding CART clinic trial on human diseases
so far. Recently, it was hypothesized that the frequent co-
occurrence of mood disorders and obesity may be charac-
terized by interconnected pathophysiology [68]. Therefore,
if neuropeptideCART is involved in both disorders it may be
useful for the individuals suﬀering the combined disorders.
Animal experiments have discovered a connection between
this peptide and mood disorder and obesity: social isolation
might downregulate the hypothalamic CART-containing
system, which in turn may lead to increased food intake
and body weight [47, 69, 70]. Interestingly, the hypothesized
connection of the CART system to depression in humans
derives from a study of an Italian family with early-onset
obesity and a missense mutation in the CART gene [71].
Just as obesity co-segregated with the mutation among the
family members, high levels of both depression and anxiety
were found in family members with the mutation [72].
Although the number of subjects in this study was small,
the results are intriguing. This is the ﬁrst suggestion that
the CART gene may be involved in depression and anxiety
in humans. It is as yet unclear whether the anxiety and
depression are consequences of other problems arising from
the mutation,or whether they are a more direct consequence
of the lack of normal CART peptides [10, 71]. Even though
the detail mechanism is unclear, these observations strongly
indicate the importance of CART gene and the normally
encoding products on both body weight control and mental
stabilizations. In other words, normal CART peptides, but
not the mutant, have a potential antidepressant role in
humans.
6.Mechanisms of CARTAntidepressant
6.1.RegulationofHPASystem. Althoughthecauseofdepres-
sion is complex, it is often described as a stress-related dis-
order. The stress response is mediated by the hypo-thalamic-
pituitary-adrenal (HPA) system. Activity of the corticotro-
pin-releasing hormone (CRH) neurons in the hypothalamic
PVN forms the basis of the activity of the HPA-axis. The
CRH neurons induce adrenocorticotropin (ACTH) release
fromthepituitary,which subsequentlycausescortisol release
from the adrenal cortex. The HPA-axis is considered to be
the “ﬁnal common pathway” for a major part of the depres-
sive symptomatology [73].
T h e r ei se v i d e n c es u g g e s t i n gar o l ef o rC A R Ti nt h er e -
gulation of the HPA-axis. First, CARTpeptidesare present in
each of the three components of the HPA-axis [74, 75]a n d
in blood [10, 76, 77]. This distribution suggests many roles
for the CART system in stress response, in addition to its
role in feeding, endocrine regulation and circadian rhythm.
Second, physiological and pharmacological studies showed
that central administration of CART dramatically increases
phosphorylation of cAMP response element binding protein
(CREB) in cell nuclei in corticotropin-releasing hormone-
producing neurons in the hypothalamic PVN in fasted as
well as fed rats at 10-min postinjection, particularly in the
medial parvocellular subdivision of the PVN [78]. CREB
is an important transcription factor, which responds to
environmental signals, CREB phosphorylation is necessary
for neuron survival. Furthermore, ultrastructural analysis
revealed that CART establishes axosomatic and axodendritic
contacts with CRH neurons in the PVN [78].
CART is capable of increasing the gene expression of
both CRH and thyrotropin-releasing hormone (TRH) in
hypophysiotropic neurons. Additionally, CART-containing
axon terminals establish synaptic relationships with hypo-
physiotropic CRH and TRH neurons.Therefore, it is possible
that through its many functions, CART may signal the HPA-
axis by more than one pathway. For example, CART regu-
lates the activity of the HPA-axis through a corticotropin-
releasing factor- (CRF- or CRH-) dependent central mech-
anism [79], and partly through a direct interaction with the
pituitary corticotropes[80, 81].Interestingly, thestimulating
eﬀect of CARTon serum ACTH concentration was observed
only 30min after ICV injection.H o w e v e r ,C A R Ts t i m u l a t e d
corticosterone release at 10, 30, 60min after ICV injection
[81]. This observation suggests that CART has an acute
eﬀect as well as a long-lasting cascade eﬀect on adrenal
gland through direct (local adrenal only) and/or indirect
(hypothalamus-pituitary-adrenal cascade) pathway. Hence,
the translation of these interactions in HPA-axis system into
identifying a novel therapeutic target is promising [11, 82,
83].
6.2. Limbic System, Dopamine, and Serotonin Transmitters.
The limbic system, which is thought to have a role in
regulating emotion, is very important for modulating aﬀect
and anxiety. It is also an important target for contemporary
antidepressants [10, 84]. CART peptides are expressed in
several parts of the limbic system, including the central and
basomedial nuclei of the amygdala, the bed nucleus of the
stria terminalis, and the hippocampus [7, 85].
The mesolimbic dopamine system is most often asso-
ciated with the rewarding eﬀects of food, sex, locomotor
activity, and drug abuse [87, 88]. The NAc(ventral striatum)
and its dopaminergic input from the ventral tegmental
area (VTA) form together the mesolimbic dopamine system
(Figure 1)[87].Giventheprominenceofanhedonia,reduced
motivation, and decreased energy level in most individuals
with depression, it has been proposed that the NAc and6 Depression Research and Treatment
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Figure 1: CART is highly expressed in the most structures of the
limbic system which is known to be the seat of the emotions. This
simpliﬁed diagram depicts the major limbic circuitry and main
pathways that may mediate the antidepressant role of CART. The
midbrain ventral tegmental area (VTA) and the connection with
the nucleus accumbens (NAc) in the ventral striatum also form
the mesolimbic dopamine pathway (square with dotted line). Both
CART mRNA and peptide are abundant in the depicted brain
regions.In humanbrain,thehighestCARTmRNAexpressionlevels
were found in hypothalamus and thalamus [86].
VTA contribute importantly to the pathophysiology and
symptomatology of depression and may even be involved in
its etiology [87, 89].
The major limbic structures, including the amygdaloid
complex, dentate gyrus of the hippocampus, medial pre-
frontal cortex, hypothalamic mammillary and supramam-
millary nucleus, and NAc,all express CARTmRNA and pro-
tein (Figure 1), suggesting a potential role for CART in the
treatment of psychiatric disorders in which stress responses,
mood and reward processes are involved [10, 30, 48, 49, 86–
90].Thedopaminergicsystem oftheNAcoperateswithin the
limbic system, which is closely related to mood. CART has
been shown to increase dopamine and serotonin turnover
in the NAc [91, 92], and both of these neurotransmitters
are important mood regulators. Therefore, the homeostatic
role of CART via dopaminergic system in these regions
may also prove to be beneﬁcial in the treatment of major
depression disease. It has been shown that CART increases
phosphorylation of CREB protein in the hypothalamus [78].
Interestingly, use of electroconvulsive therapy, a well-known
antidepressant and antipsychotic treatment, increased CART
mRNA and protein levels in the rat NAc. This increase
of CART mRNA was also accompanied by an increase in
phosphorylation of CREB[67], which indicates the potential
important mediating role of CART in the therapeutic eﬀects
of electroconvulsive shock.
CART was also found to alter the activity of the striatal
noradrenergic and corticostriatal and hypothalamic sero-
toninergic system and enhance their eﬀect on the central
dopamine system, despite the role of these eﬀects not being
completely understood [93–95]. To investigate the eﬀect of
CARTpeptidesonextracellular5-hydroxytryptamine (5-HT,
serotonin) in NAc and the dorsal raphe nucleus (DRN)—
which contains the most serotonergic neurons projected to
the forebrain, including the NAc—a microdialysis approach
was used in freely behaving rats [92]. Reverse infusion
of CART 61–102 (short form) in the DRN produced a
concentration- (10–100 microM) dependent increase in 5-
HT in the DRN. Similarly, CART 62–76 (10–100 microM)
infused into the DRN and NAc elevated 5-HT in the DRN
and NAc, respectively. Thus, CART increases extracellular 5-
HTinboththeDRNandNAc.Inaddition,infusionofhigher
dose CART 62–76 (100 microM, super short form) in the
DRN produced a signiﬁcant increase of 5-HT in the NAc.
This suggeststhepossibilityofCARTreceptorsbeingrespon-
sible for the depolarization-dependent release of 5-HT. In
summary, these results suggest that CART peptides may have
an antidepressant eﬀect through increases in extracellular
5-HT [92]. On the other hand, the ICV administration
of IgG antibodies against CART in rats upregulates mu
and serotonin 5-HT (2A) receptor in the hippocampus and
caudate. This ﬁnding demonstrates that endogenous CART
peptides in the cerebrospinal ﬂuid may exert regulatory
eﬀects on serotonin system and other signaling in the brain
[96]. Further study of depression animal model(s) will be
very interesting given the preliminary evidence of CART
levels being increased in two animal models of depression
and anxiety [64].
6.3.Energy HomeostasisandMitochondrial Booster. To deter-
mine themechanisms ofCART’smultiplefunctions, theﬁeld
has been faced with the challenge of identifying the CART
receptor and interaction partners [10]. Although the CART-
speciﬁc binding sites in culture cells and the hypothalamus
have been characterized, the receptor(s) for CART have not
yetbeenidentiﬁed[10].Recently,theﬁrst interactionprotein
for CART, the mitochondrial succinate dehydrogenase B
(SDHB) [12], was identiﬁed by a yeast two-hybrid system.
Related to this ﬁnding, CART also stimulates SDH activity
and increases ATP level and neuron survival in normal and
pathological (i.e., ischemia) conditions. Furthermore, this
action is eﬃcient at lower CART concentrations [12]. Succi-
nate dehydrogenase (mitochondrial respiratory complex II)
is a key member of both the Krebs tricarboxylic acid cycle
(TCAcycle)and the aerobic respiratory chain; both of which
are critical for intermediary metabolism and energy produc-
tion. The observations from CART knockout mice, in which
the normal relationship between CART and mitochondrial
SDH disappeared, clearly indicate that CART is involved in
thephysiologicalregulationoffeeding andenergyhomeosta-
sis (35, 36). Given its role as a SDH interaction partner and
mitochondrial booster, CART may be suitable for treatment
of some debilitating diseases, including mood disorders
(MDD), obesity/diabetes, and neurodegenerative diseases.
Furthermore,CARTisalso colocalizedwith themelanin-
concentrating hormone (MCH) and orexin-containing neu-
rons in the hypothalamic circuits that control the energyDepression Research and Treatment 7
homeostasis, which can aﬀect the vegetative function in pa-
tients suﬀering major depression [97]. CART may co-ordi-
natewith thesefactorsduringregulationoftheenergyhome-
ostasis, including in the animal depression models as well as
MDD patients.
6.4. CART Increases Other Neurotrophic Factors Particularly
BDNF. Neurotrophic factors, as survival factors, are critical
regulators of the formation, development and plasticity of
neuronalnetworks in thenervous system [28,98].Increasing
evidence suggests that neuronal plasticity and neurogenesis
play an important role in the recovery from depression.
Antidepressant treatments increase the expression of several
molecules, which are associated with neuronal plasticity
and neurogenesis, in particular the neurotrophin BDNF
and its receptor tyrosine kinase B (TrkB). BDNF is broadly
expressed in mammalian and human brain, including the
hippocampus and prefrontal cortex. BDNF together with
TrkB plays an important role in development, neural
regeneration, synaptic transmission, synaptic plasticity, and
neurogenesis [27, 28, 99–101]. Therefore new agents capable
of enhancing BDNF levels may lead aid the development of
novel therapeutic drugs for treatment of MDD and other
mental diseases. Interestingly, CART is highly expressed
in rat hippocampus and can promote the survival and
diﬀerentiation of neurons in primary hippocampal cell
cultures. This neurotrophic role is mediated by increasing
BDNF expression, and blocked by TrkB antibody [60]. The
precise mechanism underling this action is unclear. It has
been shown that CART activates the extracellular signal-
regulated kinase (ERK) pathway in pituitary-derived AtT20
cells via putative G-protein coupled receptors [102], and
this increase in the phosphorylation of ERK was conﬁrmed
in primary cortical neurons [58]. The activation of the
E R Kf a m i l yo fM A Pk i n a s e sp r o m o t e ss u r v i v a lo fn e u r o n s
eventually [103]. CART also signiﬁcantly increases the levels
of phosphorylated ERK and phosphorylated N-methyl-d-
aspartate (NMDA) receptor NR1 subunit in the spinal cord
[104]. More directly, CART has a putative transcription
activity in neuronal cells, once CART peptide enters to the
cellular nuclei, CART can induce transcription of target
genes[39]. Among these CART-associated genes/proteins, in
turn, transcription factor CREB regulates genes whose prod-
ucts are essential for prolonged neurotrophin-dependent
survival of neurons [105, 106].
In addition, inhibitory transmitter γ-aminobutyric acid
(GABA) is another crucial element in the neuroendocrine
and modulatory systems in the hypothalamus, and GABA
receptors are the targets for many psychotropic drugs
including antidepressants [107]. CART and the subunit of
the GABAA receptors are coexpressed in the hypothalamus
[107, 108] and in the midbrain [109]. It has been suggested
that the CART peptides may be used as a cotransmitter
in a subpopulation of intrinsic GABAergic terminals in the
shell of NAc, as evidenced by the intense immunoreactivity
in dense-core vesicles forming a symmetrical synapse in a
primatestudy[110].AlthoughitisnotknownhowtheCART
peptidesmodulatetherelease ofGABAfrom intrinsic striatal
terminals, the interaction between CART and the GABA
receptors might provide some critical clues regarding the
mechanism of antidepressants.
7.Concerns:Anxiety-Like Actionfor
SomeCARTPeptides
There is evidence for an involvement of CART peptides
in anxiety-like behavior [7, 10, 111]. It was reported that
in rats and mice, ICV injection of small CART peptide
fragments (89–103, super short form, 15 a.a.) increased
anxiety-like behavior in the elevated plus-maze, and ICV
administration of CART (82–103, super short form, 22 a.a.)
(0.04–5.0nmol) did not inhibit water intake and did not
aﬀectspontaneouslocomotoractivity.Theauthorssuggested
that CART might be an anxiety/arousal peptide as primary
action, and the eﬀects on food intake may be secondary due
to anxiety/arousal [112].
Inanotherstudy,ICVadministration oflongformCART
55–102, but not short form CART 62–102 (or CART 49–
89 in humans), increased anxiety-like behavior as measured
in the elevated plus-maze and in a social-interaction test
[113]. Interestingly, CART 49–89 in the biologically active
dose range had no eﬀect on time spent in open arms of
the elevated plus-maze. Therefore, two biologically relevant
formsofCARTpeptidecanbedistinguished invivobasedon
their potential to cause anxiety in mice. These results suggest
that diﬀerent CART peptides may have diﬀerent roles, and
that there might be more than one CART receptor. Thus, we
propose that the short form of CARTpeptide (CART49–89)
may be more preferred as a potential antidepressant agent.
8.ConclusionsandFutureDirections
The etiology of major depression disorder (MDD) is still
unclear. It is likely a complex of multiple factors, includ-
ing genetic, environments and psychosocial factors. Recent
studies on the involvement of neurotrophic factors in the
regulation of mood disorders and antidepressant eﬀectshave
led to the formulation of the neurotrophic hypothesis of
depression [26–29]. The currently available evidence from
molecular feature, gene expression, mutation analysis and
translational studies suggests that new neurotrophic factor
CART (or CARTPT, cocaine- and amphetamine-regulated
transcript prepropeptide) has possible therapeutic implica-
tions in the treatment of major depression and other mood
disorders and comorbid obesity. CART has the potential to
play an important role in the treatment of major depression
through several mechanisms.
(1) CART performs an antidepressant eﬀect through the
regulation of certain cascades in the signal transduc-
tion pathway by modulating kinases, other neuro-
trophic factors and neurotransmitters such as BDNF,
serotonin, dopamine, and GABA, respectively, result-
ing in increased neuronal survival and an alteration
in the synaptic plasticity positive to a treatment of
depression.8 Depression Research and Treatment
(2) CART also enhances mitochondrial activity by acting
as a partner of the key mitochondrial enzyme SDH,
therefore CART increases cellular energy in the treat-
ment of debilitating depression.
(3) CART may regulate the HPA-axis feedback loop
throughtheregulation ofcorticotropin-releasing fac-
tor (CRF or CRH), some pituitary corticotropes and
adrenal hormones, at least partly via its transcription
activity.
It is important to continue investigating the roles of
CART in the treatment of depression (including animal
models of depression), which will undoubtedly lead to an
enhanced understanding of the molecular actions of antide-
pressants. It should be noted that CART short form may
providethemostpromiseforfurtherclinicaltrials, andlower
doses of CART will have reduced side eﬀects. Moreover,
preliminary evidence of some promising roles of CART in
the regulation of serotonin, noradrenaline, and dopamine—
all of which are essential players in the mechanism of anti-
depressants—may provide important clues in the develop-
ment of novel antidepressants.
In conclusion, CART peptide has a novel antidepressant
function in mammals and humans, and CART or its deriva-
tives may be promising antidepressant treatments.
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